Importance of low diagnostic Accuracy for early Parkinson's disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Autopsy-validated studies of clinical diagnostic accuracy in early Parkinson’s disease (PD) indicate that, as compared with patients followed for a number of years, misdiagnosis is common. It is not that these individuals do not have parkinsonism (bradykinesia, cogwheel rigidity, or rest tremor), but rather the neuropathological findings do not support a diagnosis of PD, defined as loss of SN dopamine (DA) neurons in the presence of Lewy bodies. This is even true for an appreciable fraction of those with parkinsonism responding to dopaminergic medications. Thus, making a clinical diagnosis of PD can be difficult, and we have previously reported a low diagnostic accuracy in early PD, confirming an earlier study. We now summarize, for the first time in the literature, the results from these two studies in combination with a third previous study and provide further relevant commentary. In the three studies that included initial, early diagnosis, only 5 of 13 (38%), 28 of 43 (65%), and 8 of 15 (53%) patients clinically diagnosed with early PD were confirmed to have PD at autopsy. Taken together, these data from three different research groups report a diagnostic accuracy of only 58% (41 of 71) for parkinsonian subjects with an initial, early diagnosis of PD. These findings of poor diagnostic accuracy for an initial/early diagnosis of PD differ from the higher diagnostic accuracy found in autopsy studies with a final clinical diagnosis of PD following more than 10 years of follow-up and/or with retrospective reclassification of subjects after autopsy. Unfortunately, for research or therapeutic clinical trials targeting much earlier disease states, subjects must be categorized without the benefit of years of longitudinal clinical assessments. It is important to note that diagnostic inaccuracy has also been reported using clinical biomarkers for PD. The introduction of DA functional imaging has confirmed the presence of a worrisome misdiagnosis rate. Whereas I-CIT, F-DOPA, I-FP, I-ioflupane (DAT), and other DA functional scans are known to lack specificity for PD, and hence should not be used as a single test to diagnose PD, DA scans are often used as a diagnostic adjunct. If a parkinsonian subject does not have an abnormal scan, then these subjects are classified as being SWEDDs (scans without evidence of DA deficit) and thus considered not likely to have PD. In a recent review, 3.6% to 19.6% of clinically presumptive PD subjects in drug or imaging studies have been found to be SWEDDs. Relevant studies of early PD have also noted substantial proportions of SWEDDs. In the PRECEPT study, eligible patients were those who had, at the time of the screening and baseline evaluations, at least 2 of the cardinal signs of PD (resting tremor, bradykinesia, or rigidity) and no current or imminent PD disability requiring DA therapy. Of 799 such subjects, 91 (11.4%) had a negative I-CIT scan and were thus classified as SWEDDs. Similarly, in the PPMI (Parkinson Progression Markers Initiative) study, which enrolled 309 subjects with early PD, 42 were SWEDDs (13.6%). In a follow-up study of nonmotor symptoms in the PPMI cohort, 62 of 412 (15%) of enrolled subjects were SWEDDs. These results may not be entirely representative of clinical DA imaging utilization, because of their origin from clinical trials, where selection bias may arise because of pressure to enroll, and/or lowered diagnostic criteria to allow more *Correspondence to: Dr. Charles H. Adler, Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85262, USA; Email: cadler@mayo.edu
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationArizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Sue, L. I., Vedders, L., Lue, L., White III, C. L., Akiyama, H., Caviness, J. N., Shill, H. A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0664-3 · Cited by 911
Self-citationAlpha‐synuclein RT ‐Qu IC in the CSF of patients with alpha‐synucleinopathies
Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program
Beach, T. G., Adler, C. H., Sue, L. I., Serrano, G., Shill, H. A., Walker, D. G., Lue, L., Roher, A. E., Dugger, B. N., Maarouf, C., et al. (2015) · Neuropathology · doi:10.1111/neup.12189 · Cited by 460
Self-citationNalls, M. A., McLean, C. Y., Rick, J., Eberly, S., Hutten, S. J., Gwinn, K., Sutherland, M., Martinez, M., Heutink, P., Williams, N. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00178-7 · Cited by 204
Seppi, K., Scherfler, C., Donnemiller, E., Virgolini, I., Schocke, M. F. H., Goebel, G., Mair, K. J., Boesch, S., Brenneis, C., Wenning, G. K., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.8.1154 · Cited by 64
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Current and projected future economic burden of Parkinson’s disease in the U.S.
Yang, W., Hamilton, J. L., Kopil, C., Beck, J. C., Tanner, C. M., Albin, R. L., Ray Dorsey, E., Dahodwala, N., Cintina, I., Hogan, P., et al. (2020) · npj Parkinson's Disease · doi:10.1038/s41531-020-0117-1 · Cited by 657
Loh, H. W., Ooi, C. P., Palmer, E., Barua, P. D., Dogan, S., Tuncer, T., Baygin, M., & Acharya, U. R. (2021) · Electronics · doi:10.3390/electronics10141740 · Cited by 144
“The set of supportive and exclusion criteria are complex, and misdiagnosis is not uncommon due to an array of differential diagnoses, many of which are not accompanied by a decrease in dopamine levels [4,17].”
BackgroundArcher, D. B., Bricker, J. T., Chu, W. T., Burciu, R. G., McCracken, J. L., Lai, S., Coombes, S. A., Fang, R., Barmpoutis, A., Corcos, D. M., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30105-0 · Cited by 124
Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191648 · Cited by 46
Metadata
- Authors
- Beach, T. G., & Adler, C. H.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2018-10
- Volume
- 33
- Issue
- 10
- Pages
- 1551-1554
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2895530851
- Cited by
- 135
- References
- 7
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.